Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Arcus Biosciences Inc’s stock clocked out at $15.96, up 2.97% from its previous closing price of $15.50. In other words, the price has increased by $2.97 from its previous closing price. On the day, 0.6 million shares were traded. RCUS stock price reached its highest trading level at $15.97 during the session, while it also had its lowest trading level at $15.35.
Ratios:
To gain a deeper understanding of RCUS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.23 and its Current Ratio is at 5.23. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on October 21, 2024, initiated with a Neutral rating and assigned the stock a target price of $20.
On October 08, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $29.
On November 18, 2022, BofA Securities started tracking the stock assigning a Neutral rating and target price of $33.BofA Securities initiated its Neutral rating on November 18, 2022, with a $33 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 02 ’24 when Azoy Alexander sold 201 shares for $15.32 per share. The transaction valued at 3,079 led to the insider holds 19,070 shares of the business.
Azoy Alexander sold 1,357 shares of RCUS for $20,314 on Aug 13 ’24. The Chief Accounting Officer now owns 19,070 shares after completing the transaction at $14.97 per share. On Mar 27 ’24, another insider, Jarrett Jennifer, who serves as the Chief Operating Officer of the company, sold 11,551 shares for $17.55 each. As a result, the insider received 202,720 and left with 215,253 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCUS now has a Market Capitalization of 1460525184 and an Enterprise Value of 408429952. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.57 while its Price-to-Book (P/B) ratio in mrq is 2.58. Its current Enterprise Value per Revenue stands at 1.553 whereas that against EBITDA is -1.418.
Stock Price History:
Over the past 52 weeks, RCUS has reached a high of $20.31, while it has fallen to a 52-week low of $13.52. The 50-Day Moving Average of the stock is -2.40%, while the 200-Day Moving Average is calculated to be -1.61%.
Shares Statistics:
It appears that RCUS traded 763.37K shares on average per day over the past three months and 804650 shares per day over the past ten days. A total of 91.50M shares are outstanding, with a floating share count of 48.15M. Insiders hold about 47.38% of the company’s shares, while institutions hold 54.49% stake in the company. Shares short for RCUS as of 1732838400 were 8032160 with a Short Ratio of 10.52, compared to 1730332800 on 6652735. Therefore, it implies a Short% of Shares Outstanding of 8032160 and a Short% of Float of 18.100001.
